Distal lower extremity paresthesia and foot drop developing during adalimumab therapy - 21/08/11
Reprint requests: Sylvia Hsu, MD, Department of Dermatology, Baylor College of Medicine, One Baylor Plaza, FB800, Houston, TX 77030.Dallas and Houston, Texas
Abstract |
The development of tumor necrosis factor inhibitor biologic therapy is arguably one of the most significant achievements in the treatment of rheumatic diseases to date. Neurologic events suggestive of demyelination have been reported for patients receiving treatment with the antitumor necrosis factor agents etanercept and infliximab. We describe the onset of lower extremity paresthesia and foot drop in a patient who was receiving adalimumab for the treatment of psoriasis and examine the relationship of tumor necrosis factor antagonism and demyelinating disease.
Le texte complet de cet article est disponible en PDF.Plan
| Supported by Stiefel Laboratories. Funding sources: None. Conflicts of interest: None identified. |
Vol 53 - N° 5S
P. S260-S262 - novembre 2005 Retour au numéro
Article précédent
- Meningiomas after medulloblastoma irradiation treatment in a patient with basal cell nevus syndrome
- Ross M. Campbell, Russell D. Mader, Raymond G. Dufresne
- Treatment of cutaneous calcinosis in CREST syndrome by extracorporeal shock wave lithotripsy
- Agnès Sparsa, Nicolas Lesaux, Emmanuel Kessler, Jean-Marie Bonnetblanc, Sophie Blaise, Valérie Lebrun-Ly, Pierre Colombeau, Elisabeth Vidal, Christophe Bédane
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?